T47D-182R2 Cell Line

A human fulvestrant-resistant breast cancer model used to study acquired endocrine resistance, oestrogen receptor signalling, and combination therapies. Save 30% on this cell line this autumn. Use code ACA26CELL at checkout.

Contributors

Inventor Institute
Anne Lykkesfeldt Danish Cancer Society
SKU: 151890
Product description: T47D-182R2 is an adherent human breast cancer cell line that exhibits resistance to fulvestrant (Faslodex). It was developed from the parental T47D/S5 cell line through long-term exposure to 100 nM fulvestrant. The cells retain an epithelial morphology. As resistance to fulvestrant—a common second-line endocrine therapy—is a clinical challenge, T47D-182R2 represents a valuable model for studying acquired resistance mechanisms. It serves as a robust tool for identifying targeted therapies against resistant tumour cells, as well as for evaluating strategies to prevent or delay resistance emergence.
Gender: Female
Production details: Human breast cancer cell line derived from T47D/S5 by long term treatment with 100 nM fulvestrant.
Cellosaurus ID: CVCL_1D35
Parental cell line: T47D/S5
Disease: Cancer
Cat. #: 151890
Tool sub type: Continuous
Unit size: 1×10^6 cells / vial
Cancer types: Breast cancer
Research Fields: Cancer; Drug development
Organism: Human
Tissue: Breast
Gender: Female
Model: Cancer cell line
Growth properties: Adherent
Cancer Types In Detail: Breast cancer;Fulvestrant resistant
Primary citation: Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.
Format: Frozen
Shipping conditions: Dry ice
Growth medium: Phenol red free RPMI 1640 + 5% FCS + glutamax + 8ug Insulin/ml + 100 nM fulvestrant. Fetal Calf Serum (FCS) typically contains less estrogen than Fetal Bovine Serum (FBS) and is the preferred supplement for this cell line.
Subculture routine: Following thawing and counting, dilute the cell suspension with sufficient medium and distribute 5 mL each into T25 flasks to achieve a seeding density of 1.8 – 2.0 x 10^4 / cm2. Place in 37°C, 5% CO₂ incubator. Change medium after 24 hours to remove residual DMSO and then every 2-3 days. Subculture routine: Split 1:7 weekly (slow growing cell line) with Trypsin-EDTA for detachment at 37 °C for 5 minutes. Please also see detailed protocol within the Product Datasheet in the Documentation tab.
Temperature: 37°C
Atmosphere: 5% CO₂
Storage medium: 10% DMSO in FCS
References:

Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.

Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.

Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.

Images

View Gallery
Representative pictures of sensitive parental (T47D/S2 and T47D/S5); tamoxifen (TR-1 and TR-1) and fulvestrant (182R-1 and 182R-2) resistant cell lines treated for five days with dasatinib or DMSO (control). Adapted from Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.

Related Tools for Cell lines

Cat. # Tool Name
152109 T47D/S2 Cell Line Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.